Following on from my recent "Tachycardia" post, here is a new French-American paper on treatment arrhythmia:
"Breast and prostate cancers are among the most prevalent cancers worldwide. Estradiol and progesterone are major drivers for breast cancer proliferation, as well as androgens for prostate cancer. Endocrine therapies are drugs that interfere with hormone-activated pathways to slow cancer progression. Multiple new breakthrough drugs improving overall survival have recently been developed within this class. As the use of these latter drugs grows, incidence of cardiac arrhythmias has emerged as an unappreciated complication. These changes are not surprising given that sex hormones alter ventricular repolarization. Testosterone shortens action potential duration and QT interval duration, while estradiol has an opposite effect. In patients with breast cancer, selective estrogen receptor modulators are associated with more reports for long QT and Torsade de Pointes than aromatase inhibitors, likely through an estradiol-like effect on the heart. Cyclin-dependent kinase 4/6 inhibitors, a new class of anticancer drugs used in combination with endocrine therapies in hormone receptor positive breast cancer, are also variably associated with drug-induced long QT, particularly with ribociclib. In prostate cancer, androgen deprivation therapy is associated with long QT and Torsade de pointes, and possibly atrial fibrillation for abiraterone. In this review, we have summarized the clinical and preclinical data focusing on cardiac arrhythmia considerations of hormone cancer therapies."
-Patrick
ncbi.nlm.nih.gov/pubmed/306...
Cardiovasc Res. 2019 Jan 30. doi: 10.1093/cvr/cvz020. [Epub ahead of print]
Cardiac arrhythmia considerations of hormone cancer therapies.
Barber M1, Nguyen LS2, Wassermann J3, Spano JP3, Funck-Brentano C2, Salem JE1,2.
Author information
1
Department of Medicine and Clinical Pharmacology, Cardio-Oncology Program, Vanderbilt University Medical Center, Nashville, TN, USA.
2
Sorbonne Université, INSERM CIC Paris-Est, AP-HP, ICAN, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France.
3
Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, Department of Oncology, Paris, France.
PMID: 30698686 DOI: 10.1093/cvr/cvz020